Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy [1]

Movement Disorders

Volumn 21, Issue 1, 2006, Pages 123-124

  Suzuki, Kazumasa ^a   Awata, Shuichi ^a   Nakagawa, Kae ^a   Takano, Takehisa ^a   Matsuoka, Hiroo ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CREATINE KINASE; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PAROXETINE; PRAMIPEXOLE; QUETIAPINE; SELEGILINE; ZONISAMIDE;

ADULT; AKINESIA; AMNESIA; BRADYPHRENIA; CASE REPORT; CATATONIA; DEFENSE MECHANISM; DELUSION; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; GUILT; HUMAN; LETTER; MENTAL INSTABILITY; MOTOR DYSFUNCTION; MUSCLE CONTRACTURE; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RIGIDITY; STUPOR; VISUAL HALLUCINATION;

ANTIPARKINSON AGENTS; CATATONIA; COMA; DIAGNOSIS, DIFFERENTIAL; ELECTROCONVULSIVE THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33244480327     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20749     Document Type: Letter

References (10)

1. Caroff SN, Mann SC, Francis A, Fricchione GL, editors. Catatonia: from psychopathology to neurobiology. Washington DC: American Psychiatric Association; 2004.
2. Fink M, Taylor TA. Catatonia: A clinician's guide to diagnosis and treatment. New York: Cambridge University Press; 2003.
3. Swartz CM, Acosta D, Bashir A. Diminished ECT response in catatonia due to chronic neurologic condition. J ECT 2003;19: 110-114.
4. Carroll BT, Anfinson TJ, Kennedy JC, Yendrek R, Boutros M, Bilon A. Catatonic disorder due to general medical conditions. J Neuropsychiatry Clin Neurosci 1994;6:122-133.
5. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology 1988;38:1841-1844.
6. Reimer J, Kuhlmann A, Muller T. Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide. Parkinsonism Relat Disord 2002;9:115-116.
7. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or-dopaminergic malignant syndrome-due to levodopa therapy withdrawal clinical features in 11 patients. Parkinsonism Relat Disord 2003;9:175-178.
8. Mann SC, Caroff SN, Bleier HR, Welz WK, Kling MA, Hayashida M. Lethal catatonia. Am J Psychiatry 1986;143:1374-1381.
9. White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991;158:419-421.
10. Caroff SN, Mann SC, Keck PE Jr, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000;20:257-259.